SafeSpace Global Corp (SSGC): Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

RB Global (RBA) increased its stock buyback program to $1B from $500M. Q2 diluted EPS rose 34% reported, 6% adjusted. Q2 GTV grew 11% to $4.7B, net income up 31% to $143.6M. Management raised full-year GTV growth outlook to 9-11%. Hedge fund ownership declined, short interest at 10.54%.

HSBC (HSBA) declared a second interim dividend of $0.10 per share, payable in 2026, and announced share repurchases totaling ~$125M. The bank reported $22B in Q2 wealth net new money, driven by Hong Kong and wealth management. HSBC also plans $2B in simplification savings and disclosed CFO Pam Kaur's departure. The bank is an anchor investor in the NSE IPO.

Ares Capital (ARCC) raised $750M via 6.250% notes maturing in 2033, paying down bank borrowings. Q2 earnings covered dividends, but net income and NAV per share declined. Short interest is high, and loan quality slightly worsened. The move extends liquidity but reflects a slower deal environment.

Ascendis Pharma (ASND) authorized a $400M share buyback. Q2 2025 saw €315M product revenue, up 105% YoY, with €220M operating profit. Cash reserves grew to €812M. Buyback is discretionary, dependent on market conditions. YORVIPATH drove most revenue, while SKYTROFA and YUVIWEL contributed less. Costs increased due to expansion and R&D.

Halozyme Therapeutics (HALO) plans a $1.05B convertible notes offering due 2033, with an option for $150M more. Proceeds will repay some 2027 and 2028 notes, fund capped calls, and support general purposes. Q2 revenue was $481M with $287.7M operating income. The move aims to extend debt maturity but may increase interest costs.

Mechanics Bancorp (MCHB) sold $417M of auto loans near book value, retaining $13M. Management aims to reduce risk, improve liquidity, and boost profitability. Success depends on redeploying proceeds effectively. The sale's impact on earnings is uncertain, with potential gains or losses based on new investments and funding costs.